XSHE
300016
Market cap797mUSD
Oct 09, Last price
9.16CNY
1D
-0.22%
1Q
11.84%
Jan 2017
-25.61%
IPO
91.42%
Name
Beijing Beilu Pharmaceutical Co Ltd
Chart & performance
P/E
57.46
P/S
4.45
EPS
0.16
Div yield, %
0.54%
Shrs. gr., 5y
1.31%
Rev. gr., 5y
6.85%
Revenues
1.20b
+21.74%
Net income
93m
+579.29%
CFO
177m
+8.47%
Dividend
Sep 23, 20260.06 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Beijing Beilu Pharmaceutical Co., Ltd., established in 1992 and headquartered in Beijing, China, operates within the pharmaceutical industry. The company is primarily involved in the research, development, production, and commercialization of diverse medicinal products. Its offerings notably include specialized drugs like contrast agents, treatments for central nervous system conditions, and oral medications designed for diabetes. Additionally, Beilu Pharmaceutical also ventures into the manufacturing of precision medicine.
Key people
Daixue Wang
Chairman of the Board · since 2012
Hong Li
Chief Financial Officer, Director · since 2013
Xu Wang
General Manager · since 2017
Xiasi Kuang
Chief Human Resource Officer, Deputy General Manager · since 2020
Ning Liu
Deputy General Manager, Secretary of the Board · since 2010
Xianzhu Duan
Vice Chairman of the Board · since 2017
Zhongjun Su
Director · since 2010
Guo'an Feng
Independent Director · since 2013
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||